The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury

Jon G. Mabley, Pal Pacher, Kanneganti G K Murthy, William Williams, Garry J. Southan, Andrew L. Salzman, Csaba Szabo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Endogenous purines, including inosine, have been shown to exert immunomodulatory and anti-inflammatory effects in a variety of disease models. The dosage of inosine required for these effects has been shown to be between 200 and 600 mg kg because of the rapid metabolism of inosine in vivo. The aim of this study was to determine whether a metabolic resistant purine analog, INO-2002, exerts anti-inflammatory effects in an animal model of acute respiratory distress syndrome. Mice challenged with intratracheal LPS (50 μg) were treated with INO-2002 (30 or 100 mg kg, i.p.) in divided doses at either 1 and 12 h or at 5 and 16 h. After 24 h, bronchoalveolar lavage fluid was obtained to measure leukocyte infiltration by myeloperoxidase levels, lung edema by protein levels, and proinflammatory chemokine (macrophage inflammatory protein 1α) and cytokine (TNF-α, IL-1, and IL-6) levels. INO-2002 (30 and 100 mg kg) reduced the LPS-mediated infiltration of leukocytes and edema as evidenced by bronchoalveolar lavage fluid reduction in levels of myeloperoxidase and protein. INO-2002 also downregulated expression of the proinflammatory mediators macrophage inflammatory protein 1α, TNF-α, IL-1, and IL-6. Delaying the start of treatment by 5 h after LPS administration affected the potency of INO-2002 protective effects, with 100 but not 30 mg kg having anti-inflammatory effects. The inosine analog INO-2002 largely suppressed LPS-induced inflammation in vivo at doses lower than those needed for the naturally occurring purine inosine. These data support the proposal that purine analogs, resistant to metabolic breakdown, may represent a useful addition to the therapy of acute respiratory distress syndrome.

Original languageEnglish (US)
Pages (from-to)258-262
Number of pages5
JournalShock
Volume32
Issue number3
DOIs
StatePublished - Sep 2009

Fingerprint

Inosine
Acute Lung Injury
Anti-Inflammatory Agents
Macrophage Inflammatory Proteins
Adult Respiratory Distress Syndrome
Bronchoalveolar Lavage Fluid
Interleukin-1
Peroxidase
Interleukin-6
Edema
Leukocytes
Purines
Chemokines
Proteins
Down-Regulation
Animal Models
Cytokines
Inflammation
Lung
Therapeutics

Keywords

  • Adenosine
  • Cytokines
  • Inflammation
  • Inosine
  • Lung
  • Purine

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Mabley, J. G., Pacher, P., Murthy, K. G. K., Williams, W., Southan, G. J., Salzman, A. L., & Szabo, C. (2009). The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. Shock, 32(3), 258-262. https://doi.org/10.1097/SHK.0b013e31819c3414

The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. / Mabley, Jon G.; Pacher, Pal; Murthy, Kanneganti G K; Williams, William; Southan, Garry J.; Salzman, Andrew L.; Szabo, Csaba.

In: Shock, Vol. 32, No. 3, 09.2009, p. 258-262.

Research output: Contribution to journalArticle

Mabley, JG, Pacher, P, Murthy, KGK, Williams, W, Southan, GJ, Salzman, AL & Szabo, C 2009, 'The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury', Shock, vol. 32, no. 3, pp. 258-262. https://doi.org/10.1097/SHK.0b013e31819c3414
Mabley, Jon G. ; Pacher, Pal ; Murthy, Kanneganti G K ; Williams, William ; Southan, Garry J. ; Salzman, Andrew L. ; Szabo, Csaba. / The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. In: Shock. 2009 ; Vol. 32, No. 3. pp. 258-262.
@article{dd10829e422c4b95a3bbd3f06dad0ad6,
title = "The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury",
abstract = "Endogenous purines, including inosine, have been shown to exert immunomodulatory and anti-inflammatory effects in a variety of disease models. The dosage of inosine required for these effects has been shown to be between 200 and 600 mg kg because of the rapid metabolism of inosine in vivo. The aim of this study was to determine whether a metabolic resistant purine analog, INO-2002, exerts anti-inflammatory effects in an animal model of acute respiratory distress syndrome. Mice challenged with intratracheal LPS (50 μg) were treated with INO-2002 (30 or 100 mg kg, i.p.) in divided doses at either 1 and 12 h or at 5 and 16 h. After 24 h, bronchoalveolar lavage fluid was obtained to measure leukocyte infiltration by myeloperoxidase levels, lung edema by protein levels, and proinflammatory chemokine (macrophage inflammatory protein 1α) and cytokine (TNF-α, IL-1, and IL-6) levels. INO-2002 (30 and 100 mg kg) reduced the LPS-mediated infiltration of leukocytes and edema as evidenced by bronchoalveolar lavage fluid reduction in levels of myeloperoxidase and protein. INO-2002 also downregulated expression of the proinflammatory mediators macrophage inflammatory protein 1α, TNF-α, IL-1, and IL-6. Delaying the start of treatment by 5 h after LPS administration affected the potency of INO-2002 protective effects, with 100 but not 30 mg kg having anti-inflammatory effects. The inosine analog INO-2002 largely suppressed LPS-induced inflammation in vivo at doses lower than those needed for the naturally occurring purine inosine. These data support the proposal that purine analogs, resistant to metabolic breakdown, may represent a useful addition to the therapy of acute respiratory distress syndrome.",
keywords = "Adenosine, Cytokines, Inflammation, Inosine, Lung, Purine",
author = "Mabley, {Jon G.} and Pal Pacher and Murthy, {Kanneganti G K} and William Williams and Southan, {Garry J.} and Salzman, {Andrew L.} and Csaba Szabo",
year = "2009",
month = "9",
doi = "10.1097/SHK.0b013e31819c3414",
language = "English (US)",
volume = "32",
pages = "258--262",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury

AU - Mabley, Jon G.

AU - Pacher, Pal

AU - Murthy, Kanneganti G K

AU - Williams, William

AU - Southan, Garry J.

AU - Salzman, Andrew L.

AU - Szabo, Csaba

PY - 2009/9

Y1 - 2009/9

N2 - Endogenous purines, including inosine, have been shown to exert immunomodulatory and anti-inflammatory effects in a variety of disease models. The dosage of inosine required for these effects has been shown to be between 200 and 600 mg kg because of the rapid metabolism of inosine in vivo. The aim of this study was to determine whether a metabolic resistant purine analog, INO-2002, exerts anti-inflammatory effects in an animal model of acute respiratory distress syndrome. Mice challenged with intratracheal LPS (50 μg) were treated with INO-2002 (30 or 100 mg kg, i.p.) in divided doses at either 1 and 12 h or at 5 and 16 h. After 24 h, bronchoalveolar lavage fluid was obtained to measure leukocyte infiltration by myeloperoxidase levels, lung edema by protein levels, and proinflammatory chemokine (macrophage inflammatory protein 1α) and cytokine (TNF-α, IL-1, and IL-6) levels. INO-2002 (30 and 100 mg kg) reduced the LPS-mediated infiltration of leukocytes and edema as evidenced by bronchoalveolar lavage fluid reduction in levels of myeloperoxidase and protein. INO-2002 also downregulated expression of the proinflammatory mediators macrophage inflammatory protein 1α, TNF-α, IL-1, and IL-6. Delaying the start of treatment by 5 h after LPS administration affected the potency of INO-2002 protective effects, with 100 but not 30 mg kg having anti-inflammatory effects. The inosine analog INO-2002 largely suppressed LPS-induced inflammation in vivo at doses lower than those needed for the naturally occurring purine inosine. These data support the proposal that purine analogs, resistant to metabolic breakdown, may represent a useful addition to the therapy of acute respiratory distress syndrome.

AB - Endogenous purines, including inosine, have been shown to exert immunomodulatory and anti-inflammatory effects in a variety of disease models. The dosage of inosine required for these effects has been shown to be between 200 and 600 mg kg because of the rapid metabolism of inosine in vivo. The aim of this study was to determine whether a metabolic resistant purine analog, INO-2002, exerts anti-inflammatory effects in an animal model of acute respiratory distress syndrome. Mice challenged with intratracheal LPS (50 μg) were treated with INO-2002 (30 or 100 mg kg, i.p.) in divided doses at either 1 and 12 h or at 5 and 16 h. After 24 h, bronchoalveolar lavage fluid was obtained to measure leukocyte infiltration by myeloperoxidase levels, lung edema by protein levels, and proinflammatory chemokine (macrophage inflammatory protein 1α) and cytokine (TNF-α, IL-1, and IL-6) levels. INO-2002 (30 and 100 mg kg) reduced the LPS-mediated infiltration of leukocytes and edema as evidenced by bronchoalveolar lavage fluid reduction in levels of myeloperoxidase and protein. INO-2002 also downregulated expression of the proinflammatory mediators macrophage inflammatory protein 1α, TNF-α, IL-1, and IL-6. Delaying the start of treatment by 5 h after LPS administration affected the potency of INO-2002 protective effects, with 100 but not 30 mg kg having anti-inflammatory effects. The inosine analog INO-2002 largely suppressed LPS-induced inflammation in vivo at doses lower than those needed for the naturally occurring purine inosine. These data support the proposal that purine analogs, resistant to metabolic breakdown, may represent a useful addition to the therapy of acute respiratory distress syndrome.

KW - Adenosine

KW - Cytokines

KW - Inflammation

KW - Inosine

KW - Lung

KW - Purine

UR - http://www.scopus.com/inward/record.url?scp=69549108327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549108327&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e31819c3414

DO - 10.1097/SHK.0b013e31819c3414

M3 - Article

VL - 32

SP - 258

EP - 262

JO - Shock

JF - Shock

SN - 1073-2322

IS - 3

ER -